Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
<h3>Introduction</h3><h4>Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to im...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513566582767616 |
|---|---|
| author | Afsheen Raza (492657) |
| author2 | Maysaloun Merhi (4246147) Varghese Philipose Inchakalody (14153292) Roopesh Krishnankutty (1297770) Allan Relecom (14153295) Shahab Uddin (154400) Said Dermime (14153298) |
| author2_role | author author author author author author |
| author_facet | Afsheen Raza (492657) Maysaloun Merhi (4246147) Varghese Philipose Inchakalody (14153292) Roopesh Krishnankutty (1297770) Allan Relecom (14153295) Shahab Uddin (154400) Said Dermime (14153298) |
| author_role | author |
| dc.creator.none.fl_str_mv | Afsheen Raza (492657) Maysaloun Merhi (4246147) Varghese Philipose Inchakalody (14153292) Roopesh Krishnankutty (1297770) Allan Relecom (14153295) Shahab Uddin (154400) Said Dermime (14153298) |
| dc.date.none.fl_str_mv | 2022-11-22T21:18:08Z |
| dc.identifier.none.fl_str_mv | 10.1186/s12967-020-02306-y |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Unleashing_the_immune_response_to_NY-ESO-1_cancer_testis_antigen_as_a_potential_target_for_cancer_immunotherapy/21598449 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Medical biochemistry and metabolomics Oncology and carcinogenesis Cancer immunotherapy Cancer testis antigen Cancer vaccine Immune checkpoint inhibitors NY-ESO-1 Tumor microenvironment |
| dc.title.none.fl_str_mv | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Introduction</h3><h4>Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal adult tissue but frequent occurrence in multiple tumors including melanoma and carcinomas of lung, esophageal, liver, gastric, prostrate, ovarian, and bladder.</h4><h3>Main body</h3><p dir="ltr">This review summarizes current knowledge of NY-ESO-1 as efficient biomarker and target of immunotherapy. It also addresses limitations and challenges preventing a robust immune response to NY-ESO-1 expressing cancers, and describes pre-clinical and clinical observations relevant to NY-ESO-1 immunity, holding potential therapeutic relevance for cancer treatment.</p><h3>Conclusion</h3><p dir="ltr">NY-ESO-1 induces strong immune responses in cancer patients but has limited objective clinical responses to NY-ESO-1 expressing tumors due to effect of competitive negative signaling from immune-checkpoints and immune-suppressive tumor microenvironment. We propose that combination therapy to increase the efficacy of NY-ESO-1 specific immunotherapeutic interventions should be explored to unleash the immune response against NY-ESO-1 expressing tumors.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Translational Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1186/s12967-020-02306-y" target="_blank">http://dx.doi.org/10.1186/s12967-020-02306-y</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_7f0b48c2dc3368451d249a1cc48a55c2 |
| identifier_str_mv | 10.1186/s12967-020-02306-y |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21598449 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapyAfsheen Raza (492657)Maysaloun Merhi (4246147)Varghese Philipose Inchakalody (14153292)Roopesh Krishnankutty (1297770)Allan Relecom (14153295)Shahab Uddin (154400)Said Dermime (14153298)Biomedical and clinical sciencesImmunologyMedical biochemistry and metabolomicsOncology and carcinogenesisCancer immunotherapyCancer testis antigenCancer vaccineImmune checkpoint inhibitorsNY-ESO-1Tumor microenvironment<h3>Introduction</h3><h4>Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal adult tissue but frequent occurrence in multiple tumors including melanoma and carcinomas of lung, esophageal, liver, gastric, prostrate, ovarian, and bladder.</h4><h3>Main body</h3><p dir="ltr">This review summarizes current knowledge of NY-ESO-1 as efficient biomarker and target of immunotherapy. It also addresses limitations and challenges preventing a robust immune response to NY-ESO-1 expressing cancers, and describes pre-clinical and clinical observations relevant to NY-ESO-1 immunity, holding potential therapeutic relevance for cancer treatment.</p><h3>Conclusion</h3><p dir="ltr">NY-ESO-1 induces strong immune responses in cancer patients but has limited objective clinical responses to NY-ESO-1 expressing tumors due to effect of competitive negative signaling from immune-checkpoints and immune-suppressive tumor microenvironment. We propose that combination therapy to increase the efficacy of NY-ESO-1 specific immunotherapeutic interventions should be explored to unleash the immune response against NY-ESO-1 expressing tumors.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Translational Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1186/s12967-020-02306-y" target="_blank">http://dx.doi.org/10.1186/s12967-020-02306-y</a></p>2022-11-22T21:18:08ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s12967-020-02306-yhttps://figshare.com/articles/journal_contribution/Unleashing_the_immune_response_to_NY-ESO-1_cancer_testis_antigen_as_a_potential_target_for_cancer_immunotherapy/21598449CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215984492022-11-22T21:18:08Z |
| spellingShingle | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy Afsheen Raza (492657) Biomedical and clinical sciences Immunology Medical biochemistry and metabolomics Oncology and carcinogenesis Cancer immunotherapy Cancer testis antigen Cancer vaccine Immune checkpoint inhibitors NY-ESO-1 Tumor microenvironment |
| status_str | publishedVersion |
| title | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy |
| title_full | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy |
| title_fullStr | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy |
| title_full_unstemmed | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy |
| title_short | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy |
| title_sort | Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy |
| topic | Biomedical and clinical sciences Immunology Medical biochemistry and metabolomics Oncology and carcinogenesis Cancer immunotherapy Cancer testis antigen Cancer vaccine Immune checkpoint inhibitors NY-ESO-1 Tumor microenvironment |